Table 1.
Baseline patient characteristics after multiple imputation and propensity-score weighting in the MAIA and SWOG S0777 trials
| Covariate | MAIA (n = 727) |
SWOG S0777 (n = 198) |
||||
|---|---|---|---|---|---|---|
| D-Rd (n = 363) |
Rd (n = 364) |
Standardized differencea | VRd (n = 91) |
Rd (n = 107) |
Standardized differencea | |
| Age, mean (SD), years | 72.75 (4.77) | 72.65 (4.81) | 0.021 | 72.69 (5.36) | 72.65 (5.13) | 0.009 |
| Female | 40.4% | 41.9% | − 0.031 | 39.0% | 39.8% | − 0.017 |
| ISS disease stage | ||||||
| I | 20.2% | 20.6% | − 0.010 | 20.1% | 19.7% | 0.010 |
| II | 44.0% | 45.3% | − 0.026 | 44.5% | 44.8% | − 0.006 |
| III | 35.8% | 34.1% | 0.036 | 35.4% | 35.5% | − 0.002 |
| ECOG PS score | ||||||
| 0 | 42.5% | 40.9% | 0.032 | 40.1% | 40.1% | 0.001 |
| 1 | 48.9% | 50.4% | − 0.030 | 51.2% | 51.0% | 0.004 |
| ≥ 2 | 8.6% | 8.7% | − 0.003 | 8.7% | 8.9% | − 0.009 |
| Hemoglobin < 10 g/dL | 31.0% | 30.4% | 0.013 | 31.9% | 32.1% | − 0.004 |
| eGFR < 60 mL/min/1.73 m2 | 47.3% | 47.0% | 0.005 | 47.2% | 46.9% | 0.007 |
| LDH ≥ 190 U/L | 38.6% | 39.9% | − 0.027 | 39.4% | 39.0% | 0.009 |
| High cytogenetic riskb | 18.1% | 19.1% | − 0.024 | 16.4% | 16.6% | − 0.005 |
SWOG Southwest Oncology Group, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, VRd bortezomib plus lenalidomide/dexamethasone, SD standard deviation, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase
aStandardized mean differences shown in the table reflect the magnitude of the difference in baseline covariate means across trial arms within each trial. Cross-trial standardized mean differences for the MAIA versus SWOG S0777 trials, not shown in the table, were < 0.1 for all baseline covariates
bHigh cytogenetic risk was defined in the MAIA and SWOG S0777 trials as the presence of ≥ 1 high-risk cytogenetic abnormality (del17p, t[14;16], or t[4;14])